Navigation Links
New diagnostic marker for prostate cancer

Researchers of the University of Michigan, have found a gene which acts as a specific diagnostic marker for prostate cancer. Using a technique called DNA microarray analysis, which allows investigation of the activity of thousands of different genes in tissue samples. //The gene is called a-methylacyl-CoA racemase (AMACR) and it's never before been seen in association with cancer.

In this study, AMACR was found in over 90 per cent of 200 prostate cancer tissue samples. Importantly, it was not seen in benign prostate tissue or other tissue showing non-malignant change. There's no suggestion that AMACR actually causes cancer, but it does act as a marker showing that cancer is present.

It may well be that AMACR will score over the conventional prostate specific antigen (PSA) screen for prostate cancer. For PSA is found in cancer but also in benign prostate disease. AMACR looks to be far more specific. And the researchers have found the gene in other cancers too, such as colorectal, ovarian and breast cancer, which suggests it may be widely applicable as an accurate diagnostic test.


'"/>




Page: 1

Related medicine news :

1. MRI as a diagnostic tool for breast cancer
2. Mammography units and up gradation and tax cuts on diagnostic equipments in Hospitals
3. SRL Ranbaxy offers quicker bird flu diagnostic test
4. Scientists Use Salivas diagnostic Alphabets to Diagnose Disease
5. Scientific markers of aging described
6. Tumour marker for melanoma found
7. Osteoporosis and kidney stones gene marker identified
8. New heart disease marker
9. Biomarker for prostate cancer may be separated for treatment
10. Tumour marker for detecting early Recurrence of Thyroid cancer may be soon available
11. Molecular markers for early diagnosis of breast and ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/25/2016)... ... May 25, 2016 , ... ... seen a significant spike in their clients' employee participation for their wellness initiatives. ... screening by implementing a high-deductible health plan with outcome-based deductible incentives. As a ...
(Date:5/25/2016)... Jersey (PRWEB) , ... May 25, 2016 , ... ... technology firm will be selling the device branded as Stern’s Real Time Monitoring ... geared to bedbugs to the hotel and motel industry, colleges for use in dormitories, ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise ... company as Vice President of Sales. Cifolelli’s primary responsibilities include management of ... the rapidly expanding field of organizational social engineering. , “We are delighted ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
Breaking Medicine Technology: